Laboratory Tests in Diagnosis of Mastocytosis: Literature Review and Case Report

1. Valent P., Horny H-P, Li CY, Longley J.B., Metcalfe D.D., Parwaresch R.M., et al. Mastocytosis (mast cell disease). In: World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumoursof Haematopoietic and Lymphoid Tissues. Eds: Jaffe ES, Harris NL, Stein H, Vardiman JW. IARC PressLyon, France, 2001, pp291-302.Search in Google Scholar

2. Peter Valent, Cem Akin, Karin Hartmann, Gunnar Nilsson, Andreas Reiter et al. Advances in the Classification and Treatment of Mastocytosis Current Status and Outlook toward the Future, Cancer Res; 77(6) March 15, 2017.10.1158/0008-5472.CAN-16-2234535495928254862Search in Google Scholar

3. Butov J.S., Skripkin J.K., Ivanova O.L. Dermatovenereology. National guidance. Brief publication - М.: GEHOTAR-Media, 2013. - 896 pp.Search in Google Scholar

4. Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127 (20): 2391-405.10.1182/blood-2016-03-64354427069254Search in Google Scholar

5. Peter Valent. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology Hematology 2015.10.1182/asheducation-2015.1.9826637707Search in Google Scholar

6. Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett JM, Valent P, et al. Mastocytosis (mast cell disease). In: Eds: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. editors. WorldHealthOrganization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. pp 54-63.Search in Google Scholar

7. ValentP, AkinC, SperrWR, HornyHP,ArockM, LechnerK, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003; 122: 695-717.10.1046/j.1365-2141.2003.04575.x12930381Search in Google Scholar

8. Wöhrl S, Moritz KB, Bracher A et al. A c-kit mutation in exon 18 in familial mastocytosis. J Invest Dermatol. 2013; 133 (3): 839-41.10.1038/jid.2012.39423190889Search in Google Scholar

9. Nicola Wagner, Petra Staubach Mastocytosis – pathogenesis, clinical manifestation and treatment, 2018 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd. | JDDG10.1111/ddg.1341829314691Search in Google Scholar

10. Valent P, Escribano L, Broesby-Olsen S et al. European Competence Network on Mastocytosis. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014.10.1111/all.1243624836395Search in Google Scholar

11. Tefferi, A. & Pardanani, A. Systemic mastocytosis: current concepts and treatment advances. Current Hematology Reports. 2004; 3: 197-202.Search in Google Scholar

12. Nagornaya N.V., Bordyugova Ye.V., Koval A.P., Dubovaya A.V. Mastocytosis in Children: Literature Review and Own Clinical Observation. Zdorov’e rebenka. 2013. № 7 (50). Р. 173-177.10.22141/2224-0551.7.50.2013.84933Search in Google Scholar

13. Batkaev E.A., Olenich I.V., Chistyakova I.A., Avedikian S.S., Matheopoulos R.G., Malyarenko E.N., Bobrov A.M. Mastocytosis, diagnosis and treatment. Vestnik poslediplomnogo medicinskogo obrazovaniya. 2016. № 1. С. 11-16.Search in Google Scholar

14. Melikian A.L., Subortseva I.N., Goriacheva S.R., Kolosheĭnova T.I., Vakhrusheva M.V., Kovrigina A.M., Sudarikov A.B., Dvirnyk V.N., Obukhova T.N. Mastocytosis. Review of the literature and description of clinical cases. Terapevticheskij arhiv. 2014. Т. 86. № 12. Р. 127-134.10.17116/terarkh20148612127-13425804054Search in Google Scholar

15. Proshutinskaya D.V., Makoveckaya O.S. Clinical features of mastocytosis at pediatric patients. Vestnik dermatologii i venerologii. 2017. № 1.Р. 12-20.10.25208/0042-4609-2017-93-1-12-20Search in Google Scholar

16. Robyn M. Scherber and Uma Borate How we diagnose and treat systemic mastocytosis in adults. 2017 John Wiley & Sons Ltd, British Journal of Haematology10.1111/bjh.14967Search in Google Scholar

17. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012; 157:215-225.10.1159/000328760Search in Google Scholar

18. Krivolapov J.A. Bone marrow biopsy: research and practice publication. Practical medicine. 2014. -528 с. ISBN: 978-5-98811-308-9Search in Google Scholar

19. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006; 30:373–8.10.1016/j.leukres.2005.08.015Search in Google Scholar

20. Bai CG, Hou XW, Wang F, Qiu C, Zhu Y, Huang L, Zhao J, Xu JJ, Ma DL (2012) Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth. World J Gastroenterol 18(23):2929–2937. doi:10.3748/wjg.v18. i23.2929Search in Google Scholar

21. Peter ValentMastocytosis: a paradigmatic example of a rare disease with complex biology and pathology Am J Cancer Res 2013; 3(2):159-172Search in Google Scholar

22. H.-P. Horny, K. Sotlar, P. Valent Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and ImmunohistologyInt Arch Allergy Immunol 2012; 159:1–5Search in Google Scholar

23. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:579–623.10.1016/S0889-8588(05)70298-7Search in Google Scholar

24. Horny HP, Sotlar K, Valent P. Mastocytosis: state ofthe art. Pathobiology 2007; 74:121–32.10.1159/000101711Search in Google Scholar

25. Wimazal F, Sperr WR, Horny H-P, Carroll V, Binder BR, Fonatsch C, Walchshofer S, Fo¨dinger M, Schwarzinger I, Samorapoompichit P, Chott A, Dvorak AM, Lechner K, Valent P. Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol 1999; 61:66–76.10.1002/(SICI)1096-8652(199905)61:1<66::AID-AJH12>3.0.CO;2-3Search in Google Scholar

26. Khantawatana S, Carias R, Arnaout R, Hu J, Irani AM, Schwartz LB. The potential clinical utility of serum alpha-protryptase levels. J Allergy Clin Immunol 1999; 103:1092–9.10.1016/S0091-6749(99)70184-3Search in Google Scholar

27. Lennartsson J, Ronnstrand L (2012) Stem cell factor receptor/ cKit: from basic science to clinical implications. Physiol Rev 92(4): 1619–1649. doi:10.1152/physrev.00046.201110.1152/physrev.00046.2011Search in Google Scholar

28. Tsibulkina V.N., Tsibiakin N.A. Pathophysiology of mast cells in mastocytosis: implications for clinics and diagnosis. Prakticheskaya medicina. 2016. № 9 (101). Р. 7-11.Search in Google Scholar

29. Cardet JC, Akin C, Lee MJ (2013) Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 14(15):2033–2045. doi:10.1517/14656566.2013.82442410.1517/14656566.2013.824424Search in Google Scholar

30. Akin C, Kirschenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. ExpHematol 2000; 28: 140–7.10.1016/S0301-472X(99)00145-9Search in Google Scholar

31. Andres C. Garcia-Montero, Maria Jara-Acevedo, Cristina Teodosio KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients The American Society of Hematology 200610.1182/blood-2006-04-015545Search in Google Scholar

32. Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130:804–15.10.1038/jid.2009.281Search in Google Scholar

33. Daniel Elieh, Ali Komi, Todd Rambasek, Stefan Wöhrl Mastocytosis: from a Molecular Point of View Clinic Rev Allerg Immunol 2017Search in Google Scholar

34. Longley BJ, Metcalfe DD. A proposed classification of mastocytosis incorporating molecular genetics. Hematol Oncol Clin North Am 2000; 14:697–701.10.1016/S0889-8588(05)70303-8Search in Google Scholar

35. Giovanna De Matteisa, Roberta Zanott The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis Leukemia Research 39 (2015) 273–278Search in Google Scholar

36. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, García-Montero A, Sanchez-Mu~noz L, Teodosio C, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol 2016; 137:168–7810.1016/j.jaci.2015.05.008Search in Google Scholar

37. Georg Greiner, Michael Gurbisz Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis Clinical Chemistry 64:3 (2018)10.1373/clinchem.2017.277897Search in Google Scholar

38. Akin C, Kirschenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000; 28:140–7.10.1016/S0301-472X(99)00145-9Search in Google Scholar

39. Sperr WR, Horny H-P, Lechner K, Valent P. Clinical and biologic diversity of leukemias occuring in patients with mastocytosis. Leuk Lymphoma 2000; 37:473–86.10.3109/10428190009058500Search in Google Scholar

40. Metcalfe DD. The treatment of mastocytosis. J Invest Dermatol 1991; 96:55S–6S.10.1111/1523-1747.ep12469049Search in Google Scholar

41. Marone G, Spadaro G, Granata F, Triggiani M. Treatment of mastocytosis: pharmacologic basis and current concepts, Leuk Res, this issue.Search in Google Scholar

42. Turk J, Oates JA, Roberts LJ. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983; 71:189–92.10.1016/0091-6749(83)90098-2Search in Google Scholar

43. Graves L, Stechschulte DJ, Morris DC, Lukert BP. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Mineral Res 1994; 5: 1113–9.10.1002/jbmr.56500511042270775Search in Google Scholar

44. Povoa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991; 229:475–7.10.1111/j.1365-2796.1991.tb00379.xSearch in Google Scholar

45. Horan RF, Scheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85:852–5.10.1016/0091-6749(90)90067-ESearch in Google Scholar